2008 a growth year says Germany’s XClinical

By Phil Taylor

- Last updated on GMT

Related tags: Clinical research

Germany’s XClinical says 2008 was a successful year with a 20 per cent hike in revenues for its electronic data capture (EDC) and clinical data/trial management (CDM/CTM) software.

XClinical was founded in 2002 to develop and market web-based eClinical software, based on the CDISC (Clinical Data Interchange Standards Consortium) data model, that avoided the complex interfaces that plague some other systems.

The system, called MARVIN, combines EDC, CDM and CTM modules and working processes in a single online CDISC database.

While it is a relative newcomer to the eClinical space, MARVIN’s take-up has been impressive. XClinical added 20 new trials to the platform in 2008, some from old and some from new clients, and says it has not lost a single client since its formation. MARVIN has been used in more than 70 studies involving well over 50,000 patients since its introduction.

Last year’s crop of clients hailed from the USA, Japan, Germany, Czech Republic, Belgium, Switzerland and France, according to Dr. Claus Lindenau, Head of Business Development at XClinical., and included new clients contract research organisatons (CROs) and pharmaceutical companies.

Lindenau believes Xclinical’s concept of TechTransfer – in which clients are set up with the MARVIN platform and can then organise and manage their own trials – is one of the reasons for the fast growth.

Internationality is one of the essential parts of our business strategy as well as our concept of TechTransfer​”, said Lindenau. “Our intention is to build up an international network of certified partners.​“

For 2009 XClinical says it is planning to replicate last year’s success and to broaden its international network still further.

Related news

Show more

Related products

show more

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us

Products

View more

Webinars